Accès ouvert

Galectin 3 as a new therapeutic target for fibrosis and metabolic disorders in type 2 diabetes

Article scientifique 2021 Anglais

Résumé

Abstract Background: The objective of our research work was to identify the predictive factors of metabolic disorder and the pro-fibrotic factors which would be correlated with high levels of Galectin-3(Gal-3) in a population of patients with type 2 diabetes. Methods: We carried out an analytical cross-sectional study.We included 260 type 2 diabetics followed in our endocrinology department.For the purpose of determining a threshold value of Gal-3,we asked for a non-diabetic control group. The medical history interview included history of diabetes, use of antihypertensive medications, lipid-lowering medication, smoking habits and physical activity.A careful clinical examination was performed for all patients and all of them underwent a biological analysis with an assay of the plasma concentrations of Galectin-3. Results: Our study included 260 type 2 diabetics with an average age of 59.4±8.9years.The sex ratio was 0.78.We established a threshold for galectin-3 with the best sensitivity and specificity at 11.25ng/ml using the ROC curve.We found a significant positive correlation of Gal-3 with age (p<0.001),duration of diabetes (p=0.024),systolic blood pressure (p =0.032), diabetic retinopathy (p<0.001), body mass index (p=0.01), waist circumference(p<0.001), hypertension (p<0.001), dyslipidemia (p=0.023),triglyceridemia (p=0.029).An inverse association between Gal-3 level and physical activity(p=0.014),hypoplipemic treatment (p=0.040),metformin (p=0.028) and glomerular filtration rate (p<0.001) were observed. Conclusion: We established a threshold value of Gal-3 and we discovered the clinical and biological parameters correlated with the elevation of Gal-3 which would be pro-fibrosating factors.We have also demonstrated that this lectin is a key player as a new marker and therapeutic target for the control of metabolic disorders.

Citer ce document

Khelifi, D., Naçef, I., Bouzid, K., Rojbi, I., Lakhoua, Y., Mchirgui, N., Hamida, F., Khiari, K. (2021). Galectin 3 as a new therapeutic target for fibrosis and metabolic disorders in type 2 diabetes. https://doi.org/10.21203/rs.3.rs-920665/v1

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Statistiques

Consultations : 1

Téléchargements : 0